PDCD1 and neoplasm: Fraietta and co-workers found that ibrutinib increased the proliferative capacities of anti-CD19 CAR-T by decreasing immunosuppressive PD-1 (programmed cell death 1) and CD200 expression on T cells and tumor cells, respectively [15].